View of Enhancing hemophilia A management: emicizumab as a cost-effective adjunct to standard therapy for inhibitor patients

Return to Article Details Enhancing hemophilia A management: emicizumab as a cost-effective adjunct to standard therapy for inhibitor patients Download Download PDF